MIM Software, Inc. appears in FDA device records as the applicant for software regulated under 21 CFR 892.2050, the medical image management and processing system classification, product code LLZ, Class II. The supplied collection holds one linked 510(k) record, K261763 for MIM – KineticID, with a Substantially Equivalent decision dated October 26, 2026; that single record is a snapshot of the supplied filings, not a measure of total clearances, sales or safety performance. A separate clearance letter in the sources covers MIM – LesionID Pro under K251883, decided December 11, 2025. [1][7][2]
The KineticID filing
K261763 covers MIM – KineticID, received May 28, 2026 and decided October 26, 2026 as Substantially Equivalent under a Traditional clearance type. The record lists product code LLZ, regulation 892.2050, device class 2, advisory committee Radiology, and a Summary as the statement or summary type. The applicant address on the filing is 25800 Science Park Dr., Suite 180, Cleveland, OH 44122, with Sydney Lindner as contact. [1]
The FDA 510(k) Premarket Notification database entry for K261763 is the corresponding public listing for that submission. The supplied collection counts one record by pathway (510k) and one decision (SESE); the smaller record sample likewise shows one SESE decision, so the two denominators agree here rather than describing a broader portfolio. [2][1]
LesionID Pro and the predicate chain
The December 11, 2025 clearance letter for K251883 names MIM – LesionID Pro, also under 21 CFR 892.2050, Class II, product code LLZ, dated and received October 23, 2025. The letter describes the device as a standalone software application that extends the functionality of the MIM software device and as a modification to the predicate MIM software application (K243012) incorporating updates to the LesionID Pro option commercially available in the then-distributed MIM software version. [7]
A GE HealthCare product page states that the version of MIM LesionID Pro described there is not available for sale, dated June 2025. That statement concerns the described version on that page and does not establish availability status for the version covered by K251883. [8]
Company description and scale
MIM Software's own about page states that the company provides software solutions for radiation oncology, nuclear medicine, radiology, interventional radiology, and molecular, neuro, and cardiac imaging, and that it was founded in 2003 with development of its flagship software product, an abbreviation of "Medical Image Merge." The same page states that more than 3000 institutions worldwide have implemented MIM Software products. [6]
The company homepage identifies MIM Software as a GE HealthCare company and describes vendor-neutral imaging software intended to standardize workflow and simplify complex clinical scenarios. That parent-brand identification comes from MIM Software's own site; the FDA applicant of record remains MIM Software, Inc. [3]
A GE HealthCare page for MIM Software carries support and documentation links, and MIM's site lists a news item on FDA clearance of a Centiloid scaling tool to quantify amyloid plaque in brain imaging. The public documents do not include the clearance record for that tool, so its regulatory details are unknown here. [8][3]
What the record does and does not show
Across the public documents, the documented products tied to this applicant are MIM – KineticID and MIM – LesionID Pro, both radiological image-processing software under product code LLZ. The FDA final-decision feed for late 2026 lists unrelated applicants and devices, such as K262280 and K254222, and does not add MIM filings. [1][7][5]
The collection's one linked record and one SESE decision describe only what the snapshot retrieved; they do not establish total company sales, total portfolio size, or safety performance. Headquarters, customer lists, certifications and commercial availability beyond the cited statements are not documented in these sources. [1][6][8]

